Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Arecor Therapeutics 62.50p £22.47m (AREC.L) The clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity &amp; Metabolism.</li>
<li>The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic and pharmacodynamic profile regardless of body mass index levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy.</li>
<li>This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes and the American Diabetes Association's Scientific Sessions.</li>
</ul>


Arecor Therapeutics 62.50p £22.47m (AREC.L) The clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity &amp; Metabolism.
The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic and pharmacodynamic profile regardless of body mass index levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy.
This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes and the American Diabetes Association's Scientific Sessions.


Aeorema Communications / Equity Bottom-Up

<ul>
<li>The strategic communications group announces its brand experience agency Cheerful Twentyfirst, has secured a record level of contracted Cannes Lions revenue for 2026.</li>
<li>A key driver of this milestone is the exceptional client retention rate, with 92% of Cannes projects returning year-on-year, alongside an additional five new activations in 2026.</li>
<li>As the Group continues to transition from transactional project execution to multi-year, strategic partnerships the revenue visibility improves, reducing seasonality and opening broader opportunities across complementary global events. </li>
</ul>


The strategic communications group announces its brand experience agency Cheerful Twentyfirst, has secured a record level of contracted Cannes Lions revenue for 2026.
A key driver of this milestone is the exceptional client retention rate, with 92% of Cannes projects returning year-on-year, alongside an additional five new activations in 2026.
As the Group continues to transition from transactional project execution to multi-year, strategic partnerships the revenue visibility improves, reducing seasonality and opening broader opportunities across complementary global events. 


<ul>
<li>The provider of test and measurement solutions for global telecommunications, digital infrastructure and government &amp; defence markets reports finals to 31 March 2026.</li>
<li>Revenue increased 19% to £21.875m reflecting strong operational execution and growing momentum across adjacent end markets and there is a small improved gross margin to 76%.</li>
<li>This led to a 53% increase in EBITDA to £1.756m and a 73% improvement in PBT to £1.344m to give EPS growth to 0.8p from 0.36p. </li>
</ul>


The provider of test and measurement solutions for global telecommunications, digital infrastructure and government &amp; defence markets reports finals to 31 March 2026.
Revenue increased 19% to £21.875m reflecting strong operational execution and growing momentum across adjacent end markets and there is a small improved gross margin to 76%.
This led to a 53% increase in EBITDA to £1.756m and a 73% improvement in PBT to £1.344m to give EPS growth to 0.8p from 0.36p. 


<ul>
<li>The provider of expert investment, chartering and risk management advice to the shipping and energy markets updates on Trading for FY February 2026.</li>
<li>Revenue of around £135.0m is expected compared to £141.9m last year, with a lower operating profit of £13.2m against £16.7m in the prior period.</li>
<li>As expected, H2 was stronger than H1, with the Group benefitting from the depth and breadth of its diversified business. </li>
</ul>


The provider of expert investment, chartering and risk management advice to the shipping and energy markets updates on Trading for FY February 2026.
Revenue of around £135.0m is expected compared to £141.9m last year, with a lower operating profit of £13.2m against £16.7m in the prior period.
As expected, H2 was stronger than H1, with the Group benefitting from the depth and breadth of its diversified business. 


Quartix Holdings plc - Hybridan Small Cap Feast: 25 March 2026

<ul>
<li>Abingdon Health 8.25p £20.71m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech reports H1 to December 2025.</li>
<li>Reported revenue is 37% higher at £4.2m, with an EBITDA loss of £1.7m compared to an EBITDA loss of £1.9m due to continued investment in the overhead base to support future growth and contract execution.</li>
<li>The net cash is £3.7m against £1.9m last year and after a fund raising in October 2025 of £3.2m to accelerate US expansion and support execution of major contracts. </li>
</ul>


Abingdon Health 8.25p £20.71m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech reports H1 to December 2025.
Reported revenue is 37% higher at £4.2m, with an EBITDA loss of £1.7m compared to an EBITDA loss of £1.9m due to continued investment in the overhead base to support future growth and contract execution.
The net cash is £3.7m against £1.9m last year and after a fund raising in October 2025 of £3.2m to accelerate US expansion and support execution of major contracts. 


United Kingdom

Crism Therapeutics Corporation is a pharmaceutical manufacturing company. The Company specializes in improving the clinical implementation of active pharmaceutical ingredients (APIs) through local drug delivery and personalized medicines. Crism Therapeutics serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Crism Therapeutics (CRTX LN)

Hybridan Small Cap Feast: 13 August 2026

he clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with...

Hybridan

Hybridan Small Cap Feast: 4 June 2026

The strategic communications group announces its brand experience agency Cheerful Twentyfirst, has secured a record level of contracted Cannes...

Hybridan

Hybridan Small Cap Feast: 26 May 2026

The provider of test and measurement solutions for global telecommunications, digital infrastructure and government & defence markets reports...

Hybridan

Quartix Holdings plc - Hybridan Small Cap Feast: 25 March 2026

The provider of expert investment, chartering and risk management advice to the shipping and energy markets updates on Trading for FY February 2026.

Hybridan

Hybridan Small Cap Feast: 17 March 2026

Abingdon Health 8.25p £20.71m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech reports...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)